$GCTK

Glucotrack, Inc. (GCTK) filed an 8-K saying that on Aug. 4, 2026 it arranged follow-on financing totaling $5.5M through a $3.5M bridge follow-on and an interim PIPE. The bridge follow-on issued $3.5M senior secured convertible notes at 8% interest, with 22% OID, plus warrants, subject to stockholder approval for conversion and exercise.

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of August 4, 2026, between Glucotrack, Inc., a Delaware corporation (the “ Company ”), and the purchaser identified on the signature page he

GlucoTrack, Inc. said it has a definitive agreement for a private placement with institutional investors. It plans to issue 2,666,666 units at $0.75 each, including one share and one five-year warrant priced at $1.50. The company expects total gross proceeds of about $5.5 million from equity and convertible debt.

Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

GlucoTrack (NASDAQ:GCTK) shares rose more than 70% after hours after the company said nonclinical minipig data support its LT-100 program using one subcutaneous injection per visit for knee osteoarthritis pain, replacing up to 15 intradermal injections. The update follows an FDA Type C meeting in May 2026, with clinical evaluation starting as early as Q4 2026 and readout in H1 2027.

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001506983 0001506983 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Healthcare stocks moved on multiple FDA and EU updates. Novartis (NVS) won FDA approval for Fabhalta in IgA nephropathy; Merck (MRK) got FDA nod for LIPFENDRA and KEYTRUDA+Padcev in bladder cancer; Novo Nordisk (NVO) received EU approval for oral Wegovy. Lilly (LLY) agreed to buy AtaiBeckley for $6.75/share plus up to $2.50 CVR.

Glucotrack, Inc. (NASDAQ: GCTK) and its operating business Lokahi Therapeutics completed a bridge financing to fund strategic growth, including advancing the combined Glucotrack-Lokahi platform and other planned capital markets activities. The financing follows Glucotrack’s recent business combination with Lokahi. E.F. Hutton & Co. acted as exclusive advisor and placement agent.

GlucoTrack Inc. (NASDAQ:GCTK) shares rose 15.98% to $0.58 in after-hours after a 5.48% intraday drop to $0.50, according to Benzinga Pro. The company said it completed a strategic business combination with Lokahi Therapeutics, with Lokahi expected to control about 90% on a fully diluted basis after approvals and Nasdaq requirements.